ReviewCancer metastasis reviews2026
CAR-T cell therapy for pediatric solid tumors: armored CAR-T cells and beyond.
Review in Cancer metastasis reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CAR-T cell therapy, which uses endogenous T cells engineered to target specific cancer antigens, is one of the most promising recent developments in the treatment of hematologic malignancies in both children and adults. CAR-T cells have shown tremendous success in treating B-cell lymphoma, acute lymphoblastic leukemia, and multiple myeloma, and they are currently FDA-approved for the treatment of six hematologic malignancies. Its success in solid tumors has been more modest, which has been attributed to several factors including the hostile tumor microenvironment (TME), poor persistence of CAR-T cells, and difficulty directing CAR-T cells towards solid tumors. Armored CAR-T cells, which modify the TME via secreted cytokines, have shown early success in the treatment of solid pediatric malignancies. We review recent trials of CAR-T cells to treat common pediatric solid malignancies, including Ewing sarcoma, osteosarcoma, neuroblastoma, diffuse intrinsic pontine glioma, rhabdomyosarcoma, Wilms tumor, and retinoblastoma. We focused particularly on armored CAR-T cells where applicable. Armored CAR-T cells have been utilized to target a variety of tumor-associated antigens on pediatric solid tumors with early successes both in vivo and in vitro, and innovative approaches for addressing their limitations are rapidly being developed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.